Lexaria Bioscience Corp. (LEXX)
NASDAQ: LEXX
· Real-Time Price · USD
1.02
0.01 (0.99%)
At close: Jun 17, 2025, 10:45 AM
0.99% (1D)
| Bid | 1.01 |
| Market Cap | 19.87M |
| Revenue (ttm) | 525.92K |
| Net Income (ttm) | -9.38M |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -1.67 |
| Forward PE | -1.75 |
| Analyst | Buy |
| Ask | 1.04 |
| Volume | 15,420 |
| Avg. Volume (20D) | 117,152 |
| Open | 0.99 |
| Previous Close | 1.01 |
| Day's Range | 0.99 - 1.02 |
| 52-Week Range | 0.92 - 4.38 |
| Beta | 0.94 |
About LEXX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol LEXX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for LEXX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-20.12%
Lexaria Bioscience shares are trading lower. The c...
Unlock content with
Pro Subscription
5 months ago
-6.31%
Lexaria Bioscience shares are trading lower. The company announced partial final results showcasing the tolerability and glycemic control efficacy findings from human study GLP-1-H24-3.
1 month ago · accessnewswire.com
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's TechnologyPfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry Lexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23, 2...
